Cart
sales@molnova.com
Etoxybamide
CAS No. 66857-17-8
Etoxybamide( —— )
Catalog No. M27983 CAS No. 66857-17-8
Etoxybamide is a drug candidate for sedative (hypnotic).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 88 | In Stock |
|
| 5MG | 121 | In Stock |
|
| 10MG | 179 | In Stock |
|
| 25MG | 295 | In Stock |
|
| 50MG | 384 | In Stock |
|
| 100MG | 539 | In Stock |
|
| 200MG | 728 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEtoxybamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionEtoxybamide is a drug candidate for sedative (hypnotic).
-
DescriptionEtoxybamide is a drug candidate for sedative (hypnotic).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorTRPV1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number66857-17-8
-
Formula Weight147.174
-
Molecular FormulaC6H13NO3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOCCCC(=O)NCCO
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jog R, et al. Formulation design and evaluation of amorphous ABT-102 nanoparticles. Int J Pharm. 2016 Feb 10;498(1-2):153-69.
molnova catalog
related products
-
Senecionine n-oxide
Senecionine n-oxide is the primary product of pyrrolizidine alkaloid biosynthesis in root cultures of Senecio vulgaris.
-
Sibiricose A1
Sibiricose A1 is a natural product for research related to life sciences.
-
L-Ascorbic Acid 2-Ph...
L-ascorbic acid 2-phosphate (2-Phospho-L-ascorbic acid) magnesium hydrate is a long-acting vitamin C derivative that can stimulate collagen formation and expression. L-ascorbic acid 2-phosphate magnesium hydrate can be used as a culture medium supplement for the osteogenic differentiation of human adipose stem cells (hASCs). L-ascorbic acid 2-phosphate magnesium hydrate increases alkaline phosphatase (ALP) activity and expression of runx2A in hASCs during the osteogenic differentiation.
